<DOC>
	<DOCNO>NCT00299390</DOCNO>
	<brief_summary>The purpose study determine whether study drug effective safe first line treatment patient small cell lung cancer</brief_summary>
	<brief_title>Safety Efficacy Study New Chemotherapy Agent Treat Small Cell Lung Cancer</brief_title>
	<detailed_description>The study previously post Schering AG , Germany . Schering AG , Germany rename Bayer Schering Pharma AG , Germany.Bayer Schering Pharma AG , Germany sponsor trial .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Epothilones</mesh_term>
	<criteria>Histologically cytologically proven Smallcell lung cancer ( SCLC ) Stage extensive disease define presence distant metastasis At least 1 unidimensionally measureable lesion WHO performance status 0 1 No previous SCLCrelated chemotherapy No previous SCLCrelated surgery No previous radiotherapy ( except brain metastasis ) Adequate function major organ system Nervous system No Grade 2 great peripheral neuropathy Cardiovascular : No symptomatic congestive heart failure No unstable angina pectoris No arrythmia need continuous treatment No uncontrolled concurrent illness Superior vena cava syndrome obstruction vital structure Untreated malignant hypercalcemia Pleural effusion manifestation disease Extensive disease amenable radiation therapy Symptomatic brain metastasis require whole brain irradiation Any concomitant malignancy except nonmelanoma skin cancer carcinoma situ cervix</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Sagopilone</keyword>
	<keyword>Epothilone</keyword>
	<keyword>SCLC</keyword>
	<keyword>Small Cell Lung Cancer</keyword>
	<keyword>Lung Cancer</keyword>
</DOC>